Sitagliptin · Januvia

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Type 2 Diabetes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (2)
JP
  • Type 2 diabetes mellitus (Glactiv by Ono; Januvia by Banyu/MSD K.K.)
Product first approved 2009ono-pharma.com
EU
  • Type 2 diabetes mellitus (Januvia)
Product first approved 2007EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (94)
Type 2 Diabetes
NCT06952231 · University of Lahore
2024-05-21 – 2025-01-05 · Diabetes Mellitus
What this study did
NCT04271189 · Azienda Ospedaliero-Universitaria di Parma
2020-09-01 – 2024-12-31 · Newly Diagnosed Type 2 Diabetes
What this study did
NCT04304261 · Third Military Medical University
2021-07-01 – 2024-04-30 · Diabetes Mellitus, Type 2, Cognitive Functions Confusion
What this study did
NCT06770894 · Azienda Policlinico Umberto I
2019-09-24 – 2024-01-24 · Osteoporosis, Bone Loss, Postmenopausal, Diabetes Mellitus Type 2
What this study did
NCT04365517 · University of Milan
2021-12-29 – 2022-12-30 · Covid19, Diabetes Mellitus, Type 2, CKD
What this study did
NCT04017832 · Novo Nordisk A/S
2019-07-29 – 2021-10-27 · Diabetes Mellitus, Type 2
What this study did
NCT01794143 · GRADE Study Group
2013-05 – 2021-04-30 · Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
What this study did
NCT02623998 · Population Health Research Institute
2016-07-09 – 2019-11-30 · Type 2 Diabetes Mellitus
What this study did
NCT01485614 · Merck Sharp & Dohme LLC
2012-02-10 – 2019-10-09 · Diabetes Mellitus, Type 2 Diabetes
What this study did
NCT03115112 · Theracos
2017-10-12 – 2018-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT02791490 · Merck Sharp & Dohme LLC
2016-06-16 – 2018-02-01 · Type 2 Diabetes Mellitus
What this study did
NCT02738879 · Merck Sharp & Dohme LLC
2016-05-09 – 2018-01-30 · Type 2 Diabetes Mellitus
What this study did
NCT02536248 · Laval University
2015-08-01 – 2017-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT01999218 · Merck Sharp & Dohme LLC
2013-12-16 – 2017-04-18 · Type 2 Diabetes Mellitus
What this study did
NCT03125694 · Tehran University of Medical Sciences
2015-02-01 – 2017-04-01 · Uncontrolled Type 2 Diabetes Mellitus
What this study did
NCT02564211 · Merck Sharp & Dohme LLC
2015-10-26 – 2017-03-07 · Type 2 Diabetes Mellitus
What this study did
NCT02577016 · Merck Sharp & Dohme LLC
2015-11-05 – 2016-11-18 · Type 2 Diabetes Mellitus
What this study did
NCT02099110 · Merck Sharp & Dohme LLC
2014-04-22 – 2016-05-26 · Type 2 Diabetes Mellitus
What this study did
NCT01937598 · Michael A. Nauck
2013-08 – 2015-06 · Type 2 Diabetes
What this study did
NCT00790205 · Merck Sharp & Dohme LLC
2008-12-10 – 2015-03-30 · Type 2 Diabetes Mellitus
What this study did
NCT01038648 · India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals
2011-12 – 2014-12 · Type 2 Diabetes
What this study did
NCT01829464 · Takeda
2013-05 – 2014-03 · Diabetes
What this study did
NCT01334229 · Laval University
2011-04 – 2013-12 · Type 2 Diabetes Mellitus
What this study did
NCT01517321 · Ono Pharmaceutical Co., Ltd.
— · Type 2 Diabetes
What this study did
NCT01462266 · Merck Sharp & Dohme LLC
2012-01-13 – 2013-06-07 · Type 2 Diabetes Mellitus
What this study did
NCT01177384 · Merck Sharp & Dohme LLC
2011-01-25 – 2013-03-25 · Type 2 Diabetes Mellitus
What this study did
NCT01076088 · Merck Sharp & Dohme LLC
2010-11-15 – 2012-12-24 · Type 2 Diabetes Mellitus
What this study did
NCT01477853 · Merck Sharp & Dohme LLC
2011-10-24 – 2012-12-04 · Type 2 Diabetes Mellitus
What this study did
NCT01098539 · GlaxoSmithKline
2010-05 – 2012-11 · Diabetes Mellitus, Type 2
What this study did
NCT01189890 · Merck Sharp & Dohme LLC
2010-08-16 – 2012-10-31 · Type 2 Diabetes Mellitus
What this study did
NCT01106690 · Janssen Research & Development, LLC
2010-06 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT01081834 · Janssen Research & Development, LLC
2010-03 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01296412 · Merck Sharp & Dohme LLC
2011-03-11 – 2012-02-29 · Diabetes Mellitus, Type 2
What this study did
NCT01076075 · Merck Sharp & Dohme LLC
2010-06-03 – 2012-01-19 · Type 2 Diabetes Mellitus
What this study did
NCT01340768 · Merck Sharp & Dohme LLC
2010-06-22 – 2011-09-21 · Type 2 Diabetes Mellitus
What this study did
NCT00851903 · Sanofi
2009-06 – 2011-09 · Diabetes Mellitus, Type 2
What this study did
NCT00722371 · Merck Sharp & Dohme LLC
2008-09-05 – 2011-03-25 · Type 2 Diabetes Mellitus
What this study did
NCT00509262 · Merck Sharp & Dohme LLC
2007-10-09 – 2011-03-16 · Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
What this study did
NCT00509236 · Merck Sharp & Dohme LLC
2007-10-19 – 2011-03-14 · Diabetes Mellitus, Type 2, End-Stage Kidney Disease
What this study did
NCT00885352 · Merck Sharp & Dohme LLC
2009-04-15 – 2010-11-10 · Type 2 Diabetes Mellitus
What this study did
NCT01046110 · Novo Nordisk A/S
2010-01 – 2010-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01034111 · Merck Sharp & Dohme LLC
2010-03-01 – 2010-10-04 · Type 2 Diabetes
What this study did
Phase 2/3 (8)
Other / comorbidity
NCT05219409 · University of Milan
2023-07 – 2027-12 · Type 1 Diabetes
What this study did
NCT05972928 · Beni-Suef University
2024-08-07 – 2025-07-31 · Polycystic Ovary Syndrome
What this study did
NCT04409795 · Joslin Diabetes Center
2021-08-26 – 2024-12-31 · Type 1 Diabetes, Monogenic Diabetes
What this study did
NCT02882477 · Hadassah Medical Organization
2016-12 – 2018-12 · Diabetes Mellitus, Iron Metabolism Disorders, Gastroduodenal Ulcer, Optic Atrophy, Sensorineural Hearing Loss, Platelet Dysfunction
What this study did
NCT00683735 · Michael A. Nauck
2009-02 – 2013-12 · Diabetes
What this study did
NCT01600703 · University Health Network, Toronto
2012-07 – 2013-08 · Hyperlipidemia
What this study did
NCT00650143 · Ludwig-Maximilians - University of Munich
2008-03 – 2013-06 · Acute Myocardial Infarction
What this study did
NCT01093651 · Washington University School of Medicine
2010-06 – 2012-06 · Diabetes, Insulin Resistance
What this study did
Phase 2 (39)
Type 2 Diabetes
NCT05833958 · George Medicines PTY Limited
2024-09 – 2025-09 · Type 2 Diabetes
What this study did
NCT03359590 · Profil Institut für Stoffwechselforschung GmbH
2018-03-21 – 2019-07-17 · Pharmacological Action
What this study did
NCT01991197 · University College Dublin
2014-04 – 2016-01 · Psoriasis, Type 2 Diabetes Mellitus
What this study did
NCT00451113 · University of British Columbia
2006-11 – 2012-11 · Type 2 Diabetes
What this study did
NCT01414920 · Takeda
2011-08 – 2012-08 · Diabetes Mellitus, Type 2
What this study did
NCT00749190 · Boehringer Ingelheim
2008-08 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
NCT00420511 · Samuel Lunenfeld Research Institute, Mount Sinai Hospital
2007-01 – 2009-09 · Type 2 Diabetes Mellitus
What this study did
NCT00631488 · Merck Sharp & Dohme LLC
2008-02 – 2009-01 · Diabetes Mellitus, Type 2
What this study did
NCT00482079 · Merck Sharp & Dohme LLC
2003-05-13 – 2006-06-15 · Diabetes Mellitus, Type II
What this study did
NCT00481663 · Merck Sharp & Dohme LLC
2003-08-19 – 2006-05-14 · Type II Diabetes Mellitus
What this study did
NCT00127192 · Merck Sharp & Dohme LLC
2005-07 – 2006-03 · Type 2 Diabetes Mellitus
What this study did
NCT00758069 · Merck Sharp & Dohme LLC
2005-07-03 – 2006-02-13 · Diabetes Mellitus, Non-Insulin-Dependent
What this study did
NCT00371007 · Merck Sharp & Dohme LLC
2004-06-01 – 2005-04-25 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07804381 · Yonsei University
2026-12-15 – 2029-04-01 · Parkinson Disease
What this study did
NCT07717242 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-07-01 – 2029-01-31 · Bladder Urothelial Carcinoma, Bladder Cancer
What this study did
NCT07003542 · Case Comprehensive Cancer Center
2026-03-16 – 2028-06 · Glioblastoma, Brain Tumor
What this study did
NCT05947825 · Tianjin Medical University Cancer Institute and Hospital
2023-07-01 – 2026-09 · PDAC - Pancreatic Ductal Adenocarcinoma
What this study did
NCT06054815 · NeuroBo Pharmaceuticals Inc.
2023-09-14 – 2024-10-30 · NON-ALCOHOLIC STEATOHEPATITIS
What this study did
NCT05353673 · Peking University People's Hospital
2021-06-01 – 2023-02-01 · Immune Thrombocytopenia, Blood Coagulation Disorders, Thrombocytopenia, Physiological Effects of Drugs
What this study did
NCT04448587 · Rabin Medical Center
2020-10-01 – 2021-12-31 · Graft Vs Host Disease
What this study did
NCT02697253 · Icahn School of Medicine at Mount Sinai
2016-01 – 2021-07-29 · Obesity
What this study did
NCT02683525 · Sherif S. Farag
2016-02-03 – 2019-10-01 · Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
What this study did
NCT01336322 · University of Pisa
2011-05 – 2018-12 · Pre-diabetes
What this study did
NCT02576288 · University of Southern California
2016-01 – 2017-12-31 · Atherosclerosis, Inflammation
What this study did
NCT01720264 · Sherif S. Farag
2012-11-02 – 2017-12-15 · Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Hematopoetic Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
What this study did
NCT02513771 · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
2015-09 – 2017-01-10 · HIV-1 Infection
What this study did
NCT02347501 · University College Dublin
2013-11 – 2016-12 · Psoriasis
What this study did
NCT02127047 · University Hospital, Basel, Switzerland
2013-11 – 2016-08-05 · Diabetes Mellitus Type 1
What this study did
NCT01963845 · University of California, San Diego
2014-01 – 2016-01 · Non-alcoholic Fatty Liver Disease
What this study did
NCT01155284 · Sanford Health
2010-08 – 2015-03 · Type 1 Diabetes
What this study did
NCT00862719 · Indiana University
2009-03 – 2015-02 · Leukemia, Myeloid, Acute, Acute Lymphoblastic Leukemia, Myelodysplasia, Leukemia, Myelogenous, Chronic, Lymphoma, Non-Hodgkin
What this study did
NCT01257464 · University of British Columbia
2010-09 – 2012-06 · Cystic Fibrosis
What this study did
NCT01405911 · Merck Sharp & Dohme LLC
2011-08-16 – 2012-04-09 · Glucose Intolerance
What this study did
NCT00768651 · University of Alberta
2008-10 – 2011-12 · Type 1 Diabetes
What this study did
NCT00961363 · National Taiwan University Hospital
2009-12 – 2011-06 · Impaired Glucose Tolerance
What this study did
NCT00837759 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2009-02 – 2011-03 · Diabetes Mellitus Type 1, Autoimmune Diabetes
What this study did
NCT00947011 · Johns Hopkins University
2009-03 – 2010-03 · Glucose Homeostasis
What this study did
Phase 1/2 (6)
Type 2 Diabetes
NCT06329882 · Mostafa Bahaa
2024-03-30 – 2026-03-20 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
NCT07675174 · Northwell Health
2026-08-14 – 2032-07-01 · GVHD - Graft-Versus-Host Disease
What this study did
NCT07365592 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-04-09 – 2029-12-31 · Colorectal Cancer
What this study did
NCT05895201 · Indiana University
2023-11 – 2025-12 · Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
What this study did
NCT04268563 · Shahid Beheshti University of Medical Sciences
2020-01-10 – 2021-07-30 · Polycystic Ovary Syndrome, Infertility, ART
What this study did
NCT01159847 · European Foundation for the Study of Diabetes
2010-01 – 2012-12 · Type 1 Diabetes
What this study did
Phase 1 (65)
Type 2 Diabetes
NCT06204107 · Chong Kun Dang Pharmaceutical
2023-11-21 – 2023-12-06 · Type 2 Diabetes Mellitus
What this study did
NCT00813228 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2009-01-06 – 2019-11-26 · Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
What this study did
NCT05549583 · Galenicum Health
2018-04-15 – 2018-04-25 · Bioequivalence, Type 2 Diabetes
What this study did
NCT03115099 · Eli Lilly and Company
2017-05-31 – 2018-04-05 · Diabetes Mellitus, Type 2
What this study did
NCT05549570 · Galenicum Health
2017-10-22 – 2017-11-01 · Bioequivalence, Diabetes Mellitus, Type 2
What this study did
NCT02824874 · Chong Kun Dang Pharmaceutical
2016-04 – 2016-05 · Diabetes Mellitus, Type II
What this study did
NCT02827890 · Chong Kun Dang Pharmaceutical
2016-04 – 2016-05 · Diabetes Mellitus Type 2
What this study did
NCT02444364 · University of Missouri-Columbia
2015-05 – 2016-01 · Type 2 Diabetes
What this study did
NCT01557504 · Merck Sharp & Dohme LLC
2012-07-18 – 2014-04-29 · Type 2 Diabetes Mellitus
What this study did
NCT02749032 · Michael A. Nauck
2011-11 – 2014-03 · Type 2 Diabetes
What this study did
NCT01408888 · Eli Lilly and Company
2011-08 – 2012-04 · Diabetes Mellitus, Type 2
What this study did
NCT01441232 · Lexicon Pharmaceuticals
2011-10 – 2011-11 · Type 2 Diabetes Mellitus
What this study did
NCT00551590 · Ludwig-Maximilians - University of Munich
2007-12 – 2011-09 · Type 2 Diabetes Mellitus
What this study did
NCT01422590 · Samsung Medical Center
2010-05 – 2011-04 · Type 2 Diabetes Mellitus
What this study did
NCT00730275 · Merck Sharp & Dohme LLC
2008-07-18 – 2011-02-14 · Type 2 Diabetes
What this study did
NCT01093794 · Merck Sharp & Dohme LLC
2010-04 – 2010-06 · Type 2 Diabetes
What this study did
NCT01095991 · AstraZeneca
2010-03 – 2010-05 · Type 2 Diabetes Mellitus
What this study did
NCT00704132 · Merck Sharp & Dohme LLC
2007-02-14 – 2010-04-28 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT01054118 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-12 – 2010-02 · Diabetes Mellitus, Type 2
What this study did
NCT00888238 · Merck Sharp & Dohme LLC
2009-05-12 – 2009-07-21 · Type 2 Diabetes Mellitus
What this study did
NCT00830076 · Merck Sharp & Dohme LLC
2008-12-02 – 2009-05-14 · Type 2 Diabetes Mellitus
What this study did
NCT00842556 · AstraZeneca
2009-03 – 2009-05 · Type 2 Diabetes Mellitus
What this study did
NCT00511108 · Merck Sharp & Dohme LLC
2007-07-11 – 2009-02-24 · Type 2 Diabetes Mellitus (T2DM)
What this study did
NCT00971659 · Profil Institut für Stoffwechselforschung GmbH
2008-01 – 2008-11 · Type 2 Diabetes
What this study did
NCT00541229 · Merck Sharp & Dohme LLC
2007-08-24 – 2008-07-01 · Type 2 Diabetes
What this study did
NCT00929201 · Merck Sharp & Dohme LLC
2008-01 – 2008-05 · Type 2 Diabetes Mellitus
What this study did
NCT00642798 · Merck Sharp & Dohme LLC
2008-03 – 2008-03 · Diabetes Mellitus Non-insulin-dependent
What this study did
NCT00975052 · Merck Sharp & Dohme LLC
2006-01 – 2006-03 · Type 2 Diabetes
What this study did
NCT00944450 · Merck Sharp & Dohme LLC
2004-08 – 2004-11 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT07634380 · Fernando Maciel Barbosa
2026-05-14 – 2031-04-10 · Advanced Renal Cell Carcinoma, Advanced Melanoma
What this study did
NCT07541781 · Kailin Yang, MD, PhD
2026-06-11 – 2030-06-11 · Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)
What this study did
NCT07567781 · AbbVie
2026-04-30 – 2026-07-21 · Healthy Volunteers
What this study did
NCT07910682 · Guangzhou Panyu Central Hospital
2025-02-27 – 2025-03-26 · Healhty
What this study did
NCT06233201 · Bio-innova Co., Ltd
2024-06-04 – 2024-07-28 · Healthy Subjects
What this study did
NCT06233240 · Bio-innova Co., Ltd
2024-04-30 – 2024-06-12 · Healthy Subjects
What this study did
NCT05900531 · Kallyope Inc.
2022-09-21 – 2023-05-31 · Obesity
What this study did
NCT07679711 · The Affiliated Hospital of Qingdao University
2023-02-14 – 2023-03-22 · Healthy Volunteers
What this study did
NCT05453786 · SK Chemicals Co., Ltd.
2022-06-23 – 2022-08-11 · Healthy Subjects
What this study did
NCT05403281 · Dong Wha Pharmaceutical Co. Ltd.
2021-11-05 – 2022-03-28 · Healthy Subjects
What this study did
NCT05236998 · SK Chemicals Co., Ltd.
2021-11-03 – 2021-12-31 · Healthy Subjects
What this study did
NCT03790839 · Hua Medicine Limited
2019-01-31 – 2019-08-30 · Patients
What this study did
NCT02650427 · Institut National de la Santé Et de la Recherche Médicale, France
2016-02 – 2018-09 · Hepato Carcinoma
What this study did
Phase 4 (116)
Type 2 Diabetes
NCT07108985 · Yonsei University
2025-09 – 2030-08-31 · Diabetes Mellitus, Type 2, Hyperglycemia, Insulin Resistance
What this study did
NCT07452913 · Bahria University
2026-01-01 – 2026-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT06851962 · Fundación para la Investigación del Hospital Clínico de Valencia
2025-05-26 – 2026-06-30 · Diabetes Mellitus Type 2
What this study did
NCT04323189 · University of Pennsylvania
2020-08-26 – 2026-02-28 · Genetics Disease, Type2 Diabetes, Heart Failure
What this study did
NCT07531108 · Hawler Medical University
2024-11-15 – 2025-11-27 · Diabetes Mellitus, Type 2
What this study did
NCT04495881 · Beijing Chao Yang Hospital
2020-01-01 – 2025-09-01 · Type 2 Diabetes
What this study did
NCT06759922 · Bahria University
2025-01-01 – 2025-06-30 · Type 2 Diabetes Mellitus
What this study did
NCT05367063 · Shanghai Zhongshan Hospital
2022-01-05 – 2025-03-20 · Type 2 Diabetes, Cardiovascular Risk
What this study did
NCT06613750 · Zhibin Xu
2024-06-01 – 2024-07-01 · Type 2 Diabetes Mellitus, Glucotoxicity
What this study did
NCT05667220 · Beijing Chao Yang Hospital
2022-12-01 – 2023-12-31 · Type 2 Diabetes
What this study did
NCT05579119 · Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
2022-07-06 – 2023-08-24 · Type 2 Diabetes
What this study did
NCT05167513 · Getz Pharma
2021-01-01 – 2022-04-28 · Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin
What this study did
NCT02338921 · Seoul National University Bundang Hospital
2015-01 – 2021-12-31 · Type 2 Diabetes
What this study did
NCT04287387 · Peking Union Medical College Hospital
2020-03-02 – 2021-03-02 · Type2 Diabetes Mellitus
What this study did
NCT03893526 · University of Copenhagen
2019-01-25 – 2021-03-01 · Type2 Diabetes
What this study did
NCT04810507 · JW Pharmaceutical
2018-11-09 – 2021-01-05 · Type 2 Diabetes
What this study did
NCT02653209 · Royal Devon and Exeter NHS Foundation Trust
2016-11-01 – 2021-01 · Type 2 Diabetes
What this study did
NCT04916093 · Beni-Suef University
2019-12-20 – 2020-12-15 · Diabetes Mellitus, Type 2
What this study did
NCT03602638 · Chinese PLA General Hospital
2018-10-01 – 2020-12-01 · Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
What this study did
NCT02917031 · AstraZeneca
2017-01-10 – 2019-08-23 · Type 2 Diabetes Mellitus, Heart Failure
What this study did
NCT02802644 · Chung-Ang University
2016-06 – 2019-06 · Acute Coronary Syndrome, Diabetes Mellitus, Type 2
What this study did
NCT01717911 · Taipei Veterans General Hospital, Taiwan
2010-09 – 2018-12 · Type 2 Diabetes
What this study did
NCT01471808 · Sun Yat-sen University
2011-10 – 2018-12 · Diabetes Mellitus, Type 2
What this study did
NCT02556918 · Emory University
2016-01 – 2018-11-06 · Hyperglycemia
What this study did
NCT03267576 · Janssen Research & Development, LLC
2017-10-27 – 2018-10-01 · Diabetes Mellitus, Type 2
What this study did
NCT02920918 · Virginia Commonwealth University
2016-10 – 2018-09 · Heart Failure, Systolic, Diabetes Mellitus, Type 2
What this study did
NCT02639637 · Vanderbilt University
2015-12 – 2017-09 · Type 2 Diabetes Mellitus
What this study did
NCT02089438 · Lund University
2014-05 – 2017-08 · Type 2 Diabetes
What this study did
NCT02301806 · Dokkyo Medical University
2015-01 – 2017-07 · Type 2 Diabetes
What this study did
NCT02256189 · Lund University
2015-04 – 2017-06 · Type 2 Diabetes
What this study did
NCT02147925 · Sun Yat-sen University
2014-08 – 2017-04 · Non-alcoholic Fatty Liver Disease
What this study did
NCT02655757 · Li Bo
2015-12 – 2017-03-10 · Atherosclerosis, Type 2 Diabetes Mellitus
What this study did
NCT02373865 · GWT-TUD GmbH
2015-09 – 2017-01 · Diabetes Mellitus Type 2
What this study did
NCT01970462 · Kathleen Dungan
2014-01 – 2016-08 · Diabetes Mellitus, Type 2, Hyperglycemia
What this study did
NCT01859793 · Medical College of Wisconsin
2013-06 – 2016-07 · Diabetes, Atherosclerosis
What this study did
NCT02048904 · University of Missouri-Columbia
2014-01 – 2016-06 · Type 2 Diabetes, Microalbuminuria
What this study did
NCT01895569 · University of Pavia
2013-06 – 2016-06 · Type 2 Diabetes Mellitus
What this study did
NCT02312063 · Kansai Electric Power Hospital
2015-02 – 2016-05 · Diabetes Mellitus, Type 2
What this study did
NCT01845831 · Emory University
2013-08 – 2016-04 · Type 2 Diabetes
What this study did
NCT02263677 · University of Missouri-Columbia
2014-03 – 2016-01 · Type 2 Diabetes, Non-alcoholic Fatty Liver Disease
What this study did
NCT02318693 · Merck Sharp & Dohme LLC
2015-02-04 – 2015-12-15 · Type 2 Diabetes Mellitus
What this study did
NCT02072096 · Eli Lilly and Company
2014-02 – 2015-10 · Diabetes Mellitus, Type 2
What this study did
NCT01374568 · University of Alabama at Birmingham
2010-07 – 2015-09 · Type 2 Diabetes Mellitus
What this study did
NCT01744236 · Amsterdam UMC, location VUmc
2013-04 – 2015-08 · Type 2 Diabetes
What this study did
NCT01863147 · Wuhan General Hospital of Guangzhou Military Command
2013-07 – 2015-07 · Newly Diagnosed Type 2 Diabetes, Coronary Artery Disease
What this study did
NCT01449747 · The Catholic University of Korea
2011-12 – 2015-07 · Type 2 Diabetes Mellitus
What this study did
NCT01907854 · Novo Nordisk A/S
2013-12-02 – 2015-06-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02250794 · Rush University Medical Center
2014-10 – 2015-05 · Type 2 Diabetes Mellitus
What this study did
Early phase / not applicable (46)
Type 2 Diabetes
NCT02879409 · Weill Cornell Medical College in Qatar
2016-11 – 2026-10-01 · Diabetes Mellitus Type 2
What this study did
NCT07172269 · Mais Qais Hbeeb
2024-09-15 – 2025-05-26 · Diabete Mellitus, Type 2 Diabetes, Obesity Type 2 Diabetes Mellitus, Dyslipidemia in Patients With Diabetes Mellitus, Insulin Resistance
What this study did
NCT05359341 · Sadat City University
2020-09-20 – 2022-01-10 · Diabete Type 2
What this study did
NCT05035849 · Nanjing First Hospital, Nanjing Medical University
2020-01-30 – 2021-05-05 · Type 2 Diabetes
What this study did
NCT02130687 · Vanderbilt University
2014-06 – 2020-08 · Type 2 Diabetes Mellitus, Hypertension
What this study did
NCT03659461 · National University of Malaysia
2017-10-01 – 2020-01-31 · Type 2 Diabetes Mellitus, PreDiabetes
What this study did
NCT01951339 · University of Colorado, Denver
2013-10 – 2018-06 · Type 2 Diabetes, Cardiovascular Disease
What this study did
NCT01703637 · Lin Liao
2012-10 – 2016-12 · Type 2 Diabetes Mellitus
What this study did
NCT02900417 · Second Affiliated Hospital of Soochow University
2016-09 – 2016-11 · Type 2 Diabetes
What this study did
NCT01512797 · Blandine Laferrere
2012-07 – 2016-08 · Type 2 Diabetes Mellitus
What this study did
NCT01073826 · University of Zurich
2010-02 – 2016-06 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT02443922 · Foundation for the National Institutes of Health
2015-06 – 2015-12 · Type 2 Diabetes
What this study did
NCT01901861 · Lund University
2013-07 – 2015-12 · Type 2 Diabetes
What this study did
NCT01260246 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2010-12 – 2015-04 · Type 2 Diabetes, Nonalcoholic Steatohepatitis
What this study did
NCT01183104 · Japan Association for Diabetes Education and Care
2010-08 – 2015-01 · Type 2 Diabetes
What this study did
NCT00673894 · Garvan Institute of Medical Research
2008-04 – 2014-11 · Type 2 Diabetes
What this study did
NCT01413542 · Vanderbilt University
2011-11 – 2014-07 · Hypertension, Diabetes Type 2
What this study did
NCT00659711 · University at Buffalo
2008-03 – 2013-12 · Type 2 Diabetes
What this study did
NCT01751321 · Research Clinical Centre of the Russian Railways, JSC
2013-05 – 2013-10 · Type 2 Diabetes
What this study did
NCT01642108 · Niigata Medical Center
2012-07 – 2013-06 · Type 2 Diabetes
What this study did
NCT00775684 · University of Pennsylvania
2008-10 – 2012-11 · Pre-diabetes, Type 2 Diabetes
What this study did
NCT01624116 · Services Hospital, Lahore
2011-08 – 2011-09 · Diabetes, Type 2
What this study did
NCT01092663 · KineMed
2010-03 – 2011-07 · Diabetes Mellitus, Type 2
What this study did
NCT00466518 · University of Oklahoma
2007-04 – 2011-01 · Kidney Transplant, Type 2 Diabetes
What this study did
NCT00747383 · The Royal Bournemouth Hospital
2008-09 – 2010-09 · Type 2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06587698 · Peking University Third Hospital
2024-08-21 – 2029-07-01 · Polycystic Ovarian Syndrome
What this study did
NCT05042505 · Medanta, The Medicity, India
2022-01-01 – 2026-02-27 · Diabetes Mellitus, Liver Transplant; Complications
What this study did
NCT07937436 · Dexa Medica Group
2023-08-09 – 2023-08-19 · Healthy Volunteers
What this study did
NCT01879228 · University of Pennsylvania
2013-06 – 2020-03 · Cystic Fibrosis, Pancreatic Insufficiency
What this study did
NCT04061473 · University Hospital, Gentofte, Copenhagen
2019-04-02 – 2019-08-20 · Diabetes After Total Pancreatectomy
What this study did
NCT05480007 · Shanghai 10th People's Hospital
2011-01-30 – 2018-12-01 · NAFLD
What this study did
NCT01140438 · Norwegian University of Science and Technology
2009-03 – 2018-11 · Diabetes
What this study did
NCT02940184 · University of Copenhagen
2016-06 – 2018-10 · Physiology
What this study did
NCT03593135 · Sheikh Zayed Federal Postgraduate Medical Institute
2017-07-15 – 2017-11-14 · Randomized Controlled Trial, Diabetes Mellitus
What this study did
NCT02336659 · Hvidovre University Hospital
2014-04 – 2016-06 · Severe Obesity
What this study did
NCT01488279 · University of Vermont
2012-09 – 2015-12 · Pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
What this study did
NCT01741103 · University at Buffalo
2011-06 – 2013-09 · Diabetes Type I
What this study did
NCT01272583 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2011-03 – 2012-10 · Type 1 Diabetes, Hypoglycemia
What this study did
NCT00721552 · Amsterdam UMC, location VUmc
2008-10 – 2012-06 · Diabetes Mellitus, Steroid Diabetes, Glucocorticoid-induced Diabetes, Beta-cell Function
What this study did
NCT01006018 · Emory University
2011-07 – 2011-12 · Prediabetic State
What this study did
NCT00696982 · Assaf-Harofeh Medical Center
2008-06 – 2009-06 · Diabetes Mellitus, Arterial Stiffness
What this study did
NCT00795275 · University of Colorado, Denver
2008-01 – 2008-11 · Obesity
What this study did
Used as active comparator (92)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (39)
Type 2 Diabetes
NCT06246799 · The University of Texas Health Science Center at San Antonio
2024-11-07 – 2029-06-30 · Type 2 Diabetes (Adult Onset)
What this study did
NCT06560333 · Eurofarma Laboratorios S.A.
2026-11-30 – 2029-02-28 · Diabetes Mellitus, Type 2
What this study did
NCT07073768 · Khyber Medical College, Peshawar
2025-07-01 – 2026-12-30 · Diabetes Mellitus Type 2, Glycemic Control for Diabetes Mellitus
What this study did
NCT03076112 · Seoul National University Bundang Hospital
2017-04-25 – 2022-08-31 · Type 2 Diabetes Mellitus
What this study did
NCT04801199 · Cadila Pharnmaceuticals
2020-01-26 – 2021-02-11 · Uncontrolled Type 2 Diabetes Mellitus
What this study did
NCT03061214 · Novo Nordisk A/S
2017-08-28 – 2019-04-15 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02849080 · Novo Nordisk A/S
2016-09-20 – 2019-03-27 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02607865 · Novo Nordisk A/S
2016-02-15 – 2018-03-28 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT02043054 · University of Leicester
2013-12-16 – 2017-09-29 · Type 2 Diabetes Mellitus, Cardiovascular Disease
What this study did
NCT01984606 · Boehringer Ingelheim
2015-01 – 2017-02 · Diabetes Mellitus, Type 2
What this study did
NCT02173457 · Chipscreen Biosciences, Ltd.
2014-09 – 2017-01 · Type 2 Diabetes
What this study did
NCT02254291 · Novo Nordisk A/S
2014-10-02 – 2015-11-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01930188 · Novo Nordisk A/S
2013-12-02 – 2015-10-12 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01455870 · Intarcia Therapeutics
2013-05 – 2015-07 · Type 2 Diabetes
What this study did
NCT02949193 · Dong-A ST Co., Ltd.
2013-05 – 2015-05 · Type 2 Diabetes Mellitus
What this study did
NCT01455909 · Intarcia Therapeutics
2013-02 – 2014-07 · Type 2 Diabetes
What this study did
NCT01703221 · Merck Sharp & Dohme LLC
2012-10-24 – 2014-04-25 · Type 2 Diabetes Mellitus
What this study did
NCT01834274 · Takeda
2013-06 – 2014-03 · Diabetes Mellitus, Type 2
What this study did
NCT01549964 · Takeda
2012-04 – 2014-03 · Glycemic Control
What this study did
NCT01529541 · JW Pharmaceutical
2011-05 – 2013-10 · Type 2 Diabetes Mellitus
What this study did
NCT01289990 · Boehringer Ingelheim
2011-02 – 2013-05 · Diabetes Mellitus, Type 2
What this study did
NCT00838903 · GlaxoSmithKline
2009-02 – 2013-04 · Diabetes Mellitus, Type 2
What this study did
NCT01602003 · LG Life Sciences
2009-12 – 2012-05 · Type 2 Diabetes Mellitus
What this study did
NCT01106677 · Janssen Research & Development, LLC
2010-05 – 2012-05 · Diabetes Mellitus, Type 2
What this study did
NCT01177813 · Boehringer Ingelheim
2010-07 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01137812 · Janssen Research & Development, LLC
2010-07 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT00958269 · Phenomix
2009-08 – 2011-11 · Type 2 Diabetes Mellitus, Renal Impairment
What this study did
NCT00998686 · Phenomix
2009-11 – 2011-11 · Type 2 Diabetes Mellitus
What this study did
NCT00770081 · Novartis
2008-09 – 2011-04 · Diabetes Mellitus, Type 2, Renal Insufficiency
What this study did
NCT00976937 · Sanofi
2009-08 – 2011-03 · Type 2 Diabetes Mellitus
What this study did
NCT00754988 · Hoffmann-La Roche
2008-10 – 2011-03 · Diabetes Mellitus Type 2
What this study did
NCT00616811 · Novartis
2008-01 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00666458 · AstraZeneca
2008-04 – 2009-03 · Type 2 Diabetes
What this study did
Phase 2/3 (2)
Type 2 Diabetes
NCT00734474 · Eli Lilly and Company
2008-08 – 2012-07 · Diabetes Mellitus, Type 2
What this study did
NCT00860288 · Novartis Pharmaceuticals
2009-02 – 2011-03 · Diabetes Mellitus, Type 2
What this study did
Phase 2 (21)
Type 2 Diabetes
NCT02689362 · Eurofarma Laboratorios S.A.
2017-08-08 – 2018-08-09 · Diabetes Mellitus, Type 2
What this study did
NCT02647320 · Daiichi Sankyo
2016-01 – 2017-01-31 · Type 2 Diabetes Mellitus
What this study did
NCT02324010 · Royal Adelaide Hospital
2015-07 – 2017-01 · Gastroparesis, Diabetes Mellitus
What this study did
NCT01824264 · Novartis Pharmaceuticals
2015-11 – 2016-11 · Type 2 Diabetes Mellitus
What this study did
NCT02405260 · vTv Therapeutics
2015-03 – 2016-09 · Diabetes Mellitus, Type 2
What this study did
NCT02111096 · Eli Lilly and Company
2014-04 – 2015-09 · Diabetes Mellitus, Type 2
What this study did
NCT02202161 · GlaxoSmithKline
2014-08-27 – 2015-01-30 · Diabetes Mellitus, Type 2
What this study did
NCT01936025 · Profil Institut für Stoffwechselforschung GmbH
2013-10 – 2014-04 · Type 2 Diabetes Mellitus
What this study did
NCT01475461 · Pfizer
2011-11 – 2013-01 · Type 2 Diabetes Mellitus
What this study did
NCT01376323 · GlaxoSmithKline
2011-07-13 – 2012-09-17 · Diabetes Mellitus, Type 2
What this study did
NCT01969357 · Jiangsu HengRui Medicine Co., Ltd.
2011-06 – 2012-06 · Type 2 Diabetes
What this study did
NCT01338870 · Pfizer
2011-06 – 2012-03 · Diabetes Mellitus, Type 2
What this study did
NCT01336738 · Pfizer
2011-06 – 2012-03 · Diabetes, Type 2
What this study did
NCT00881530 · Boehringer Ingelheim
2009-03 – 2011-05 · Diabetes Mellitus, Type 2
What this study did
NCT01059825 · Merck Sharp & Dohme LLC
2010-02-24 – 2011-01-20 · Diabetes Mellitus, Type 2
What this study did
NCT00901979 · Novartis Pharmaceuticals
2009-04 – 2010-06 · Type 2 Diabetes Mellitus
What this study did
NCT00642278 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2008-04 – 2009-01 · Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
What this study did
NCT00716092 · Boehringer Ingelheim
2008-07 – 2008-11 · Diabetes Mellitus, Type 2
What this study did
NCT00760344 · Takeda
2007-03 – 2008-03 · Diabetes Mellitus
What this study did
Phase 1/2 (2)
Type 2 Diabetes
NCT07374328 · Second Affiliated Hospital of Guangzhou Medical University
2025-06-01 – 2026-08-31 · Type 2 Diabetes
What this study did
NCT01619332 · Novartis Pharmaceuticals
2012-03 – 2013-09 · Type II Diabetes
What this study did
Phase 1 (6)
Type 2 Diabetes
NCT04982705 · IlDong Pharmaceutical Co Ltd
2021-07-07 – 2022-12-30 · Type 2 Diabetes
What this study did
NCT05266404 · AstraZeneca
2022-03-21 – 2022-05-31 · Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus)
What this study did
NCT03646721 · Dong-A ST Co., Ltd.
2018-08-29 – 2020-05-07 · Diabetes Mellitus, Type 2
What this study did
NCT01933672 · Pfizer
2013-10 – 2014-03 · Type 2 Diabetes Mellitus
What this study did
NCT00976261 · GlaxoSmithKline
2009-10-17 – 2010-09-05 · Diabetes Mellitus, Type 2
What this study did
NCT00871507 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2009-04 – 2009-07 · Diabetes Mellitus, Type 2
What this study did
Phase 4 (19)
Type 2 Diabetes
NCT07711171 · Fudan University
2024-08-19 – 2026-10-30 · Type 2 Diabetes Mellitus, Cognitive Impairment
What this study did
NCT04298684 · Centre Hospitalier Universitaire de la Guadeloupe
2021-01-01 – 2024-07-01 · Diabetes Mellitus, Type 2, Thyroid Nodule (Benign)
What this study did
NCT05386186 · Peking University People's Hospital
2022-01-01 – 2024-03-31 · Diabetes Mellitus, Type 2, Severe Insulin Deficient Diabetes
What this study did
NCT03959501 · The University of Hong Kong
2017-08-16 – 2020-10-16 · Type 2 Diabetes, Ketonemia
What this study did
NCT02480465 · Chong Kun Dang Pharmaceutical
2015-01 – 2017-03 · Diabetes Mellitus, Type 2
What this study did
NCT02512523 · Handok Inc.
2015-08-27 – 2016-09-26 · Type 2 Diabetes Mellitus
What this study did
NCT02200991 · Sanofi
2014-08 – 2015-11 · Type 2 Diabetes Mellitus
What this study did
NCT02008682 · Novo Nordisk A/S
2013-12 – 2014-11 · Diabetes, Diabetes Mellitus, Type 2
What this study did
NCT01785043 · Anna Cruceta
2013-03 – 2014-09 · DIABETES Mellitus Type 2 Not Well Controlled
What this study did
NCT01490918 · The Catholic University of Korea
2012-04 – 2014-09 · Type 2 Diabetes Mellitus
What this study did
NCT01398592 · Novartis Pharmaceuticals
2011-06 – 2012-06 · Diabetes Mellitus Type 2
What this study did
NCT00751114 · Sanofi
2008-11 – 2011-07 · Diabetes Mellitus, Type 2
What this study did
NCT01193296 · Novartis
2010-06 – 2011-06 · Type 2 Diabetes Mellitus
What this study did
NCT00957060 · Sanofi
2009-07 – 2010-10 · Diabetes Mellitus, Type 2
What this study did
NCT00780715 · University of Dundee
2008-12 – 2009-10 · Diabetes Mellitus, Type 2
What this study did
Other / comorbidity
Semaglutide vs Sitagliptinactive not recruiting
NCT05195944 · University Health Network, Toronto
2022-10-26 – 2026-12 · Liver Transplant; Complications, Diabetes Mellitus, NASH - Nonalcoholic Steatohepatitis, NAFLD
What this study did
NCT03101930 · Vanderbilt University Medical Center
2017-05-01 – 2021-06-24 · Obesity, PreDiabetes
What this study did
NCT03208465 · CHEOL WHAN LEE, M.D., Ph.D
2017-08-07 – 2019-08-01 · Diabetes Mellitus, Coronary Disease
What this study did
Early phase / not applicable (3)
Type 2 Diabetes
NCT06187285 · Medanta, The Medicity, India
2024-01-01 – 2025-06-01 · Type 2 Diabetes
What this study did
NCT02628392 · Daiichi Sankyo Co., Ltd.
2015-11 – 2016-09 · Type2 Diabetes Mellitus
What this study did
Other / comorbidity
NCT06147518 · Institute of Liver and Biliary Sciences, India
2023-12-20 – 2024-12-31 · Compensated Cirrhosis, Decompensated Cirrhosis
What this study did
Appears in other studies (6)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (4)
Type 2 Diabetes
NCT02577003 · Merck Sharp & Dohme LLC
2015-11-09 – 2016-11-25 · Type 2 Diabetes Mellitus
What this study did
NCT01545388 · Merck Sharp & Dohme LLC
2012-02-23 – 2013-03-12 · Type 2 Diabetes Mellitus
What this study did
NCT00855166 · AstraZeneca
2009-02 – 2011-12 · Type 2 Diabetes Mellitus
What this study did
Phase 1 (1)
Type 2 Diabetes
NCT02956044 · Theracos
2016-11 – 2017-03 · Type2 Diabetes Mellitus
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT06515652 · Hamdard University
2023-09-01 – 2024-08-30 · Metabolic Syndrome
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Type 2 Diabetes: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sitagliptin (Januvia): this drugApprovedSmall moleculeDPP-4Partial signal
NCT00086502: Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24 (Baseline and week 24): Sitagliptin 100 mg -0.85 Percent (95% CI -0.98 to -0.72) vs Placebo -0.15 Percent (95% CI -0.28 to -0.03)
NCT00087516: Change From Baseline in A1C at Week 24 (Weeks 0-24): Sitagliptin 100 mg -0.61 Percent (95% CI -0.74 to -0.49) | Sitagliptin 200 mg -0.76 Percent (95% CI -0.88 to -0.64) vs Placebo 0.18 Percent (95% CI 0.06 to 0.3)
Acarbose (Precose / Glucobay)
ApprovedUS marketing discontinued
Small moleculeAlpha-glucosidasenot yet gradedNo reviewed efficacy summary in this indication
AfrezzaApprovedPeptideInsulinPartial signal
NCT04974528: HbA1c change at week 26 (ITT, n=117 vs 113): Afrezza +0.19 vs rapid-acting insulin analog +0.01; difference 0.18 percentage points (95% CI -0.07 to 0.44); non-inferiority (0.4% margin) not met, one-sided adjusted p=0.058. missed
NCT01451398: Change in HbA1c from baseline to week 24: Technosphere Insulin + oral agents -0.82% (n=177) vs Technosphere powder (placebo) -0.42% (n=176); difference -0.40% (95% CI -0.57 to -0.23), p<0.0001 (CT.gov posted results).
Alogliptin (Nesina)ApprovedSmall moleculeDPP-4Partial signal
NCT02856113: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) missed
NCT00968708: Percentage of Participants With Primary Major Adverse Cardiac Events (MACE) (From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).): Alogliptin 11.3% vs Placebo 11.8%
Bexagliflozin (Brenzavvy)ApprovedSmall moleculeSGLT2Reliable signal
NCT02769481: Change From Baseline in HbA1c at Week 60 (Baseline and Week 60): Bexagliflozin -0.7 percentage of glycated hemoglin (Standard Error 0.058) vs Glimepiride -0.66 percentage of glycated hemoglin (Standard Error 0.058)
NCT03259789: Change From Baseline in HbA1c at Week 24 for Double-blind Group (Baseline to week 24): Double-blind Group: Bexagliflozin 20 mg -1.09 percentage of HbA1c (Standard Error 0.076) vs Double-blind Group: Placebo -0.56 percentage of HbA1c (Standard Error 0.075)
Canagliflozin (Invokana)ApprovedSmall moleculeSGLT2Partial signal
NCT03170518: Week 26 HbA1c change: -0.37% canagliflozin 100/300 mg vs +0.39% placebo; least-squares mean difference -0.76 percentage points (95% CI -1.25 to -0.27; p=0.002).
NCT02065791: Primary composite outcome (end-stage kidney disease, doubling of serum creatinine, or renal/cardiovascular death): HR 0.70 (95% CI 0.59-0.82; P<0.001), canagliflozin vs placebo, 30% risk reduction
Colesevelam (Welchol)ApprovedSmall moleculeBile acid sequestrantnot yet gradedNo reviewed efficacy summary in this indication
Dapagliflozin (Farxiga / Forxiga)ApprovedSmall moleculeSGLT2Partial signal
NCT01392677: Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02)
NCT00984867: Adjusted Mean Change in HbA1c Levels (Baseline to Week 24): Dapagliflozin -0.45 Percent (95% CI -0.55 to -0.35) vs Placebo 0.04 Percent (95% CI -0.06 to 0.14)
Dulaglutide (Trulicity)ApprovedPeptideGLP-1 receptorReliable signal
NCT03495102: Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04)
NCT01394952: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) (From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)): Dulaglutide 594/4949 vs Placebo 663/4952
Empagliflozin (Jardiance)ApprovedSmall moleculeSGLT2Reliable signal
NCT01131676: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1%
NCT03429543: HbA1c change at week 26, empagliflozin pooled (10 mg and 25 mg) vs placebo: adjusted mean difference -0.84% (95% CI -1.50 to -0.19), p=0.0116. Treatment failure by week 26 in the small monotherapy cohort: 50.0% vs 60.0%, Fisher p=1.0 (CT.gov posted results).
Ertugliflozin (Steglatro)ApprovedSmall moleculeSGLT2Reliable signal
NCT01986881: Time to First Occurrence of MACE (Composite Endpoint of Major Adverse Cardiovascular Events [Cardiovascular Death, Non-fatal Myocardial Infarction or Non-fatal Stroke]) (On-Treatment + 365-day Approach) (Overall Cardiovascular Study) (Up to approximately 6 years): Ertugliflozin 5 mg (Overall Cardiovascular Study) 3.64 Events per 100 Person-years | Ertugliflozin 15 mg (Overall Cardiovascular Study) 4.16 Events per 100 Person-years | Placebo (Overall Cardiovascular Study) 4.01 Events per 100 Person-years | All Ertugliflozin (Overall Cardiovascular Study) 3.9 Events per 100 Person-years
NCT01958671: Change in A1C at Week 26 versus placebo: ertugliflozin 5 mg −0.99 percentage points (95% CI −1.22 to −0.76; p<0.001); ertugliflozin 15 mg −1.16 percentage points (95% CI −1.39 to −0.93; p<0.001).
Glimepiride (Amaryl)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glipizide (Glucotrol)
ApprovedUS marketing discontinued
Small moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Glyburide (DiaBeta)ApprovedSmall moleculeSulfonylurea receptor (SUR1)not yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (NovoLog)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Aspart (Fiasp)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Insulin Degludec (Tresiba)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT00982644: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment (Week 0, Week 52): IDeg OD -1.06 percentage of glycosylated haemoglobin (Standard Deviation 1.01) vs IGlar OD -1.19 percentage of glycosylated haemoglobin (Standard Deviation 0.97)
Insulin Detemir (Levemir)
ApprovedUS marketing discontinued
PeptideInsulin receptor (basal)Partial signal
NCT00856986: Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26. (Week 0 (Randomisation), week 26): Insulin Detemir + Lira 1.8 -0.51 Percentage point of total HbA1c (Standard Error 0.07) vs Lira 1.8 0.02 Percentage point of total HbA1c (Standard Error 0.07)
NCT00283751: HbA1c at 52 weeks: decreased from 8.6% to 7.2% with insulin detemir vs 8.6% to 7.1% with insulin glargine (no significant difference between arms); non-inferiority of detemir to glargine demonstrated.
Insulin Efsitora Alfa (Onswik)ApprovedProtein / enzyme therapeuticInsulin receptor (basal)Partial signal
NCT05662332: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545)
NCT05275400: Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority] (Baseline, Week 26): 500 U/mL - Insulin Efsitora -0.81 Percentage of HbA1c (Standard Error 0.0302) vs 100 U/mL - Insulin Degludec -0.72 Percentage of HbA1c (Standard Error 0.0424)
Insulin Glargine (Lantus)ApprovedPeptideInsulin receptor (basal)Partial signalNo reviewed efficacy summary in this indication
Insulin Glargine (Basaglar)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT03338010: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062)
NCT02302716: Change From Baseline to 24 Weeks in Hemoglobin A1c (HbA1c) (Baseline, 24 weeks): LY2963016 -1.25 Percentage of glycosylated hemoglobin (Standard Error 0.066) vs LANTUS® -1.22 Percentage of glycosylated hemoglobin (Standard Error 0.067)
Insulin Glargine (Toujeo)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT01499082: Change in HbA1c From Baseline to Month 6 Endpoint (Baseline, Month 6): HOE901-U300 -0.83 percentage of hemoglobin (Standard Error 0.06) | Lantus -0.83 percentage of hemoglobin (Standard Error 0.061)
Insulin Glulisine (Apidra)ApprovedPeptideInsulin receptorPartial signal
NCT00135057: Primary endpoint (A1C change from baseline to week 24, noninferiority of carbohydrate-counting vs a simple fixed-dose algorithm for mealtime insulin glulisine, both arms on insulin glargine as basal): simple algorithm -1.46%, carb count -1.59%; difference -0.13% (95% CI -0.35 to 0.09%), within the pre-specified 0.5% noninferiority margin. Enrollment (281 randomized) matches this NCT exactly.
Insulin Icodec (Awiqli)ApprovedPeptideInsulin receptor (basal)Partial signal
NCT06340854: Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89)
NCT04760626: Change in Glycated Haemoglobin (HbA1c) (Baseline (week 0), week 52): Insulin Icodec -1.68 Percentage of HbA1c (Standard Error 0.09) vs Once Daily Basal Insulin Analogue -1.31 Percentage of HbA1c (Standard Error 0.12)
Insulin Lispro (Humalog)ApprovedPeptideInsulin receptorReliable signalFeatured results are non-efficacy only in this race
Insulin Lispro (Lyumjev)ApprovedPeptideInsulin receptorPartial signal
NCT03952143: Change From Baseline in Hemoglobin A1c (HbA1c) (Baseline, Week 26): LY900014 -0.56 Percentage of HbA1c (Standard Error 0.046) vs Insulin Lispro (Humalog) -0.63 Percentage of HbA1c (Standard Error 0.061)
NCT03214380: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 (Baseline, Week 26): LY900014 -0.38 percentage of HbA1c (Standard Error 0.042) vs Insulin Lispro (Humalog) -0.43 percentage of HbA1c (Standard Error 0.042)
Insulin NPH (Humulin N)ApprovedPeptideInsulin receptornot yet gradedNo reviewed efficacy summary in this indication
Linagliptin (Tradjenta)ApprovedSmall moleculeDPP-4Partial signal
NCT01243424: The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years
NCT03429543: Primary HbA1c outcome at week 26: adjusted mean difference linagliptin versus placebo -0.34 percentage points (95% CI -0.99 to 0.30; p=0.2935). missed
Liraglutide (Victoza)ApprovedPeptideGLP-1 receptorReliable signal
NCT00318461: Change in Glycosylated A1c (HbA1c) at Week 26 (week 0, week 26): Lira 0.6 + Met -0.69 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.2 + Met -0.97 Percentage point of total HbA1c (Standard Error 0.07) | Lira 1.8 + Met -1 Percentage point of total HbA1c (Standard Error 0.07) vs Met Mono 0.09 Percentage point of total HbA1c (Standard Error 0.09) | Met + Glim -0.98 Percentage point of total HbA1c (Standard Error 0.07)
NCT00318422: HbA1c change from baseline at 26 weeks (added to glimepiride): liraglutide 1.2/1.8mg -1.1% (baseline 8.5%) vs placebo +0.2% (baseline 8.4%, P<0.0001) vs rosiglitazone -0.4% (baseline 8.4%, P<0.0001)
Lixisenatide (Adlyxin / Lyxumia)ApprovedPeptideGLP-1 receptorPartial signal
NCT00707031: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054)
NCT00688701: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 (Baseline, Week 12): Lixisenatide (Two-Step Titration) -0.73 percentage of hemoglobin (Standard Error 0.116) | Lixisenatide (One-Step Titration) -0.85 percentage of hemoglobin (Standard Error 0.119)
Metformin (Glucophage)
ApprovedUS marketing discontinued
Small moleculeAMPKReliable signal
NCT00004992: Diabetes incidence: 11.0 (placebo) vs 7.8 (metformin) vs 4.8 (lifestyle) cases per 100 person-years; metformin reduced incidence by 31% vs placebo (95% CI 17-43%)
Pioglitazone (Actos)ApprovedSmall moleculePPAR-gammanot yet gradedNo reviewed efficacy summary in this indication
Pramlintide (Symlin)
ApprovedUS marketing discontinued
PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
SAR341402ApprovedPeptideInsulin receptorPartial signal
NCT03211858: Change in Glycated Hemoglobin A1c (HbA1c) From Baseline to Week 26 (Baseline, Week 26): SAR341402 -0.38 percentage of HbA1c (Standard Error 0.042) vs NovoLog/NovoRapid -0.3 percentage of HbA1c (Standard Error 0.041)
Saxagliptin (Onglyza)
ApprovedUS marketing discontinued
Small moleculeDPP-4Reliable signal
NCT00121667: Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07)
NCT00121641: Hemoglobin A1c (A1C) Changes From Baseline at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg — Baseline Mean: 7.91 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.43 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 5 mg — Baseline Mean: 7.98 Percentage of glycosylated hemoglobins (Standard Error 0.11); Adjusted Mean Change from Baseline: -0.46 Percentage of glycosylated hemoglobins (Standard Error 0.1) | Saxagliptin 10 mg — Baseline Mean: 7.85 Percentage of glycosylated hemoglobins (Standard Error 0.09); Adjusted Mean Change from Baseline: -0.54 Percentage of glycosylated hemoglobins (Standard Error 0.1) vs Placebo — Baseline Mean: 7.88 Percentage of glycosylated hemoglobins (Standard Error 0.1); Adjusted Mean Change from Baseline: 0.19 Percentage of glycosylated hemoglobins (Standard Error 0.1)
Semaglutide (Ozempic)ApprovedPeptideGLP-1 receptorReliable signal
NCT03819153: Primary composite kidney outcome (kidney failure, sustained >=50% eGFR decline, or death from kidney/cardiovascular causes): 331 first events (semaglutide) vs 410 first events (placebo); HR 0.76 (95% CI 0.66-0.88), P=0.0003.
NCT01720446: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (Time from randomisation up to end of follow-up (scheduled at week 109)): Semaglutide 6.6% vs Placebo 8.9%
Semaglutide (Rybelsus)ApprovedPeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Tirzepatide (Mounjaro)ApprovedPeptideGLP-1/GIP receptor (dual)Partial signal
NCT04255433: Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (From randomization (week 0) up to week 259): Tirzepatide (MTD) 801/6586 vs 1.5 mg Dulaglutide 862/6579
NCT05260021: Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg) (Baseline, Week 30): Pooled Doses of Tirzepatide (5 mg, 10 mg) -2.03 percentage of HbA1c (Standard Error 0.165) | Placebo -0.23 percentage of HbA1c (Standard Error 0.229)
Miglitol (Glyset)US approval withdrawnSmall moleculeAlpha-glucosidasePartial signalNo reviewed efficacy summary in this indication
Repaglinide (Prandin / NovoNorm)US approval withdrawnSmall moleculeSUR1 (short-acting)Partial signalNo reviewed efficacy summary in this indication
AlbenatidePhase 3PeptideGLP-1 receptorPartial signalNo reviewed efficacy summary in this indication
AleniglipronPhase 3Small moleculeGLP-1 receptorWeak signal
NCT05762471: Placebo-adjusted mean weight decrease 6.2% (p<0.0001) at 12 weeks with GSBR-1290 120mg (n=37) vs placebo (n=27); 67% achieved >=6% and 33% >= 10% weight loss vs 0% for placebo
Anagliptin (Suiny)Phase 3Small moleculeDPP-4Partial signal
NCT01529528: HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo.
NCT01529541: Change in HbA1c from baseline to week 24: anagliptin (CWP-0403) -0.85% vs sitagliptin -0.83%; mean difference -0.02% (95% CI -0.22 to 0.18%); non-inferiority established.
ASC30Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Berberine Ursodeoxycholate (HTD1801)Phase 3Small moleculeAMPK pathway / NLRP3 inflammasome (dual)Reliable signal
NCT06350890: SYMPHONY 1 (NCT06350890, n=408): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.3%, statistically superior to placebo
NCT06353347: SYMPHONY 2 (NCT06353347, n=551): mean change in HbA1c from baseline at Week 24 with HTD1801 was -1.2%, statistically superior to placebo
BerobenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT06897202: Dose-dependent body weight decrease up to 10.2% and HbA1c reduction up to 2.2% at the highest weekly dose
BGM0504Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
BofanglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
CagrilintidePhase 3PeptideAmylin receptor, Amylin/calcitonin receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Cagrilintide / Semaglutide (CagriSema)Phase 3PeptideAmylin receptor, GLP-1 receptor, Amylin/calcitonin receptor (dual)Reliable signal
NCT05394519: Change in body weight at week 68: -13.7% with CagriSema vs -3.4% with placebo; estimated difference -10.4 percentage points (p<0.001)
NCT06534411: Primary endpoints: CagriSema 1.0 mg/1.0 mg superior to tirzepatide 5 mg for weight loss at week 60 (12.4% vs 9.1%) and non-inferior for HbA1c reduction (1.71% vs 1.67%) (2026-09-21).
Chiglitazar (Bilessglu)Phase 3Small moleculePPAR (pan-agonist)Reliable signal
NCT04807348: RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008.
NCT02173457: CMAS trial, primary endpoint HbA1c change from baseline at week 24: chiglitazar 32mg and 48mg both non-inferior to sitagliptin 100mg, with treatment differences of -0.04% (95% CI -0.22 to 0.15) and -0.08% (95% CI -0.27 to 0.10) vs sitagliptin (arm sizes n=245/246/248, total 739, matching this trial's design and enrollment of 740)
CofrogliptinPhase 3Small moleculeDPP-4Reliable signal
NCT04564872: HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin
NCT04556851: HbA1c change from baseline to week 24, LS mean difference vs placebo: cofrogliptin (HSK7653) 10 mg -0.63% (95% CI: -0.81, -0.46); 25 mg -0.59% (95% CI: -0.77, -0.42); both p < 0.0001
Dapagliflozin / Linagliptin (Dapalina)Phase 3Small moleculeSGLT2;DPP-4Partial signal
NCT06329674: Change in HbA1c at Week 24: -0.77% AJU-A51 vs +0.10% linagliptin+placebo; LS mean difference -0.88% (95% CI -1.07, -0.68), p<0.0001
Dorzagliatin (Huatangning)Phase 3Small moleculeGlucokinasePartial signal
NCT04531631: Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). missed
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Efmedaglutide Alfa (Shanmeining)Phase 3Protein / enzyme therapeuticGLP-1 receptorPartial signal
NCT06235086: Primary endpoint, HbA1c change at week 28: each TG103 dose non-inferior to dulaglutide 1.5 mg (treatment policy analysis); 15 mg lowered HbA1c 1.38% (CSPC, 2026-09-30).
EfpeglenatidePhase 3PeptideGLP-1 receptorPartial signal
NCT03353350: Change in HbA1c from baseline to week 30 vs placebo: efpeglenatide 2 mg -0.5% (95% CI -0.9 to -0.2), p=0.0054; 4 mg -0.8% (-1.2 to -0.5), p<0.0001; 6 mg -1.0% (-1.4 to -0.7), p<0.0001 (AMPLITUDE-M, Rosenstock 2022, Diabetes Care).
Efsubaglutide AlfaPhase 3Protein / enzyme therapeuticGLP-1 receptorReliable signal
NCT04994288: HbA1c change from baseline at week 24 (SUPER-1, phase III stage): 1 mg dose -1.73% (95% CI -20.98,-16.83 mmol/mol), 3 mg dose -2.15% (95% CI -25.68,-21.31 mmol/mol); estimated treatment difference vs placebo -1.26% (1 mg, 95% CI -17.39,-10.06 mmol/mol) and -1.68% (3 mg, 95% CI -22.08,-14.64 mmol/mol), both CIs excluding zero.
NCT04998032: HbA1c change from baseline at week 24 (SUPER-2, add-on to metformin): Efsubaglutide 3 mg -1.80% vs placebo -0.74%; estimated treatment difference -1.06% (p<0.001)
ElecoglipronPhase 3Small moleculeGLP-1 receptorReliable signal
NCT06579105: HbA1c reduction over 26 weeks: 1.9% with elecoglipron 75 mg (highest dose) vs 0.2% with placebo
Enavogliflozin (Envlo)Phase 3Small moleculeSGLT2Reliable signal
NCT04634500: Adjusted mean change in HbA1c at Week 24: enavogliflozin -0.80% vs dapagliflozin -0.75%; treatment difference -0.04% (95% CI -0.21% to 0.12%), meeting the pre-specified non-inferiority margin of 0.35%
NCT04632862: Placebo-adjusted mean change in HbA1c from baseline at week 24 in the enavogliflozin 0.3 mg group: -0.99% (95% confidence interval -1.24%, -0.74%).
EnicepatidePhase 3PeptideGLP-1 receptor, GLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Evogliptin (Suganon)Phase 3Small moleculeDPP-4Reliable signal
NCT04170998: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001)
NCT02949193: HbA1c change from baseline at 24 weeks: -0.59% with evogliptin 5mg (n=112) vs -0.65% with sitagliptin 100mg (n=110), both add-on to metformin; between-group difference 0.06 percentage points (95% CI -0.10 to 0.22), demonstrating non-inferiority.
Exendin-4 Fc Fusion (JY09)Phase 3Protein / enzyme therapeuticGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
Gemigliptin (Zemiglo)Phase 3Small moleculeDPP-4Reliable signal
NCT03842267: LSM difference in HbA1c change at week 24 (gemigliptin add-on vs placebo, on background dapagliflozin + metformin): −0.66% (SE 0.07), 95% CI −0.80% to −0.52%.
NCT02831361: Change in HbA1c from baseline at Week 24, between-group mean difference (gemigliptin 50 mg vs placebo, added to insulin ± metformin): -0.7 percentage points (95% CI -0.9 to -0.4), p<0.0001
GosogliptinPhase 3Small moleculeDPP-4Partial signal
NCT03088670: Primary, HbA1c change at week 12 (monotherapy stage): 8.61% to 7.41% with gosogliptin vs 8.7% to 7.34% with vildagliptin (each p<0.05 vs baseline); the between-group difference was not significant and no non-inferiority test or margin is reported. Week 36 not reported. Target HbA1c <=7.0%: 41% vs 44% (p=0.53).
GZR33Phase 3PeptideInsulin receptor (basal)not yet gradedNo reviewed efficacy summary in this indication
HDG1901Phase 3PeptideGLP-1 receptorPartial signal
NCT06739044: HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met.
HDM1002Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
HDM1005Phase 3PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
Omarigliptin (Marizev)
Phase 3(overall)
Small moleculeDPP-4
Reliable signal(overall)
NCT01755156: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Phase A) (Baseline and Week 24): Omarigliptin (Phase A) -0.54 Percent (95% CI -0.69 to -0.4) vs Placebo to Omarigliptin (Phase A) 0 Percent (95% CI -0.14 to 0.15)
NCT01698775: Change From Baseline in Glycosylated Hemoglobin (A1C) at Week 24 (Baseline and Week 24): Omarigliptin (Phase A) -0.77 Percent (95% CI -1 to -0.54) vs Placebo to Omarigliptin (Phase A) -0.44 Percent (95% CI -0.67 to -0.21)
Prusogliptin (Shanzeping)Phase 3Small moleculeDPP-4Reliable signal
NCT04161430: HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo.
NCT04218734: Change in HbA1c at week 24: −0.70% (DBPR108 + metformin) vs −0.07% (placebo + metformin); upper limit of the 95% CI for the between-group difference was −0.39, below the 0% superiority margin (P < .001).
RetagliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Teneligliptin (Tenelia)Phase 3Small moleculeDPP-4Partial signal
NCT01805830: Change in HbA1c from baseline to week 16, teneligliptin (MP-513) vs placebo (both plus metformin): between-group difference -0.78 percentage points; fasting plasma glucose difference -1.24 mmol/L (22.42 mg/dL).
NCT01798238: Change in HbA1c at week 24, teneligliptin 20mg vs placebo: difference -0.94% (LS mean 95% CI -1.22, -0.65), p<0.001; fasting plasma glucose difference -1.21 mmol/L (95% CI -1.72, -0.70), p<0.001.
Trelagliptin (Zafatek)Phase 3Small moleculeDPP-4Weak signal
NCT02512068: Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089)
NCT02324569: Change in HbA1c From Baseline at the End of Treatment Period I (End of Treatment Period I - End of the Screening Period) (End of the screening period (Week 0) and End of Treatment Period I (Up to Week 12)): Treatment Group I -0.56% ± 0.070 vs Treatment Group II 0.07% ± 0.067; p=<0.0001 (Treatment Group I vs Treatment Group II)
Vildagliptin (Galvus)Phase 3Small moleculeDPP-4Partial signal
NCT00099866: At the study end, significant HbA(1c) reductions from baseline were seen with both vildagliptin (-1.0 +/- 0.1%, P < 0.001) and metformin (-1.4 +/- 0.1%, P < 0.001) missed
YogliptinPhase 3Small moleculeDPP-4Partial signalNo reviewed efficacy summary in this indication
Retagliptin / Metformin (Ruilintang)Phase 1Small moleculeDPP-4, AMPKPartial signalNo reviewed efficacy summary in this indication

Large race: only the 76 furthest-along competitors are listed; 75 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Compare side by side

9 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

(11 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Januvia (Sitagliptin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 2Glioblastoma, Brain TumorRecruiting
Est. primary completion 2027-06 · NCT07003542 · CT.gov ↗
What to watch
November 2027 (1)
Phase 4Breast CancerRecruiting
Est. primary completion 2027-11-01 · NCT07436663 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Phase 1Advanced Renal Cell Carcinoma, Advanced MelanomaRecruiting
Est. primary completion 2028-04-10 · NCT07634380 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Bladder Urothelial Carcinoma, Bladder CancerRecruiting
Est. primary completion 2028-06-30 · NCT07717242 · CT.gov ↗
What to watch
July 2028 (1)
Early phase / not applicablePolycystic Ovarian SyndromeRecruiting
Est. primary completion 2028-07-01 · NCT06587698 · CT.gov ↗
What to watch
2029 (4)
March 2029 (1)
Phase 2Parkinson DiseaseNot yet recruiting
Est. primary completion 2029-03-01 · NCT07804381 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1Glioma, Glioblastoma, Recurrent Glioma, Recurrent Glioblastoma, Grade 4 Malignant Glioma of Brain (Disorder)Recruiting
Est. primary completion 2029-06-11 · NCT07541781 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Type 2 DiabetesNot yet recruiting
Est. primary completion 2029-09-01 · NCT07108985 · CT.gov ↗
What to watch
December 2029 (1)
Phase 1/2Colorectal CancerRecruiting
Est. primary completion 2029-12-01 · NCT07365592 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 1/2GVHD - Graft-Versus-Host DiseaseRecruiting
Est. primary completion 2030-07-01 · NCT07675174 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 4DiabetesNot yet recruiting
Est. primary completion 2031-11 · NCT06813014 · CT.gov ↗
What to watch

See the full readout calendar ↗